Pipeline Moves: trial terminations in colorectal cancer, cardiovascular infections, and kidney injury
The Clinical Trials Arena team also reviews endpoint achievement in liver disease, and trial completions in metabolic syndrome and pouchitis.
By
Cardiovascular
Latest in
Cardiovascular
EASD 2022: interactions between DPP-4Is and HbA1c variability in type 2 diabetes
Data have shown that the early initiation of DPP-4Is may delay the need for insulin in T2D patients with low…
By
EASD 2022: empagliflozin significantly reduces insulin use in HF patients
Key opinion leaders have said that SGLT-2 inhibitors such as empagliflozin will increasingly be prescribed for type 2 diabetes.
By
Top tweets: Tea consumption and mortality risk – and more
Clinical Trials Arena lists five of the top tweets on cardiology in August 2022 based on data from GlobalData’s Pharmaceuticals…
Study underscores the relationship between social conditions and heart disease
The results could help health professionals and policymakers plan interventions for the most vulnerable diabetic CVD patients.
By
AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials
The Farxiga treatment offered a 10% and 29% reduction in death from any cause and total hospitalisation for HF, respectively.
Pfizer discontinues development of dilated cardiomyopathy drug emprumapimod
The decision to cancel development of emprumapimod is not expected to substantially affect projected cardiomyopathy drug sales.
By
Myovant & Pfizer’s MyFembree receives nod from the FDA for endometriosis
GlobalData expects MyFembree, a combination therapy developed by Myovant and Pfizer, to be successful in the endometriosis space.
By